Why cost and treatment length are some of the biggest concerns for drug manufacturers.
Erin Johanek, PharmD, RPh
The current and future treatments for the $10 billion condition.
The present and bright future of cholesterol treatments.
How pipeline promises—and disappointments—are impacting patients with diabetes.
The latest in RA therapies, and what you can expect from the pipeline.